黄伟 - 华中师范大学

个人简介

2014.9至今：副教授, 硕士研究生导师，华中师范大学化学学院 2013.9-2014.8：副教授, 硕士研究生导师，华中农业大学植物科学技术学院 2009.3-2013.8：博士后、副研究员，南京大学生命科学学院-江苏先声药业集团 2002.9-2008.12：硕博连读研究生，华中师范大学化学学院有机化学专业 2008.1-2008.6：交流学生，美国Wayne State University 药物发现专业 1998.9-2002.6：本科生，安庆师范大学化学专业

研究领域

针对严重危害人类健康的恶性肿瘤等重大疾病领域的临床需求，重点基于特定亚型/突变型激酶的适度选择性抑制剂和蛋白水解靶向嵌合体（PROTACS）两条策略，研究与开发用于精准治疗的靶向药物

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Z huo, L. S.;# Wang, M. S.;# Wu, X. F.;# Xu, H. C.;# Gong, Y.; Yu, Z. C.; Tian, Y. G.; Pang, C.; Hao, G. F.; Huang, W.;* Yang, G. F.* Discovery of Next-Generation Tropomyosin Receptor Kinase (TRK) Inhibitors for Combatting Multiple Resistance Associated with Protein Mutation. J. Med. Chem. 2021, 64, 15503-15515. Zhuo, L. S.;# Wu, X. F.;# Wang, M. S.; # Xu, H. C.; Yang, F. P.; Tian, Y. G.; Zhao, X. E.; Ming, Z. H.; Zhu, X. L.; Hao, G. F.;* Huang, W.* Structure–activity relationship study of novel quinazoline-based 1,6-naphthyridinones as MET inhibitors with potent antitumor efficacy. Eur. J. Med. Chem. 2020, 208, 112785. Wang, M. S.;# Xu, H. C.;# Gong, Y.;# Qu, R. Y.; Zhuo, L. S.;* Huang, W.* Efficient Arylation o2,7-Naphthyridin-1(2H)‑one with Diaryliodonium Salts and Discovery of a New Selective MET/AXL Kinase Inhibitor. ACS. Comb. Sci. 2020, 22, 457-467. Xu, H. C.;# Wang, M. S.;# Wu, X. F.;# Zhuo, L. S.*; Huang, W.*; She, N. F.* Discovery of N-substituted-3-phenyl-1,6-naphthyridinone Derivatives Bearing Quinoline Moiety as VEGFR-2 Selective Type II c-Met Kinase Inhibitors against VEGFR-2. Bioorg. Med. Chem. 2020, 28, 115555. Wu, X. F.;# Zhuo, L. S.;# Wang, F.; Huang, W.;* Hao, G. F.;* Yang, G. F.* Auto in silico ligand directing evolutionto facilitate the rapid and efficient discovery of drug lead. iScience 2020, 23, 101179. Wang, M. S.;# Zhuo, L. S.;# Yang, F. P.;# Wang, W. J.; Huang, W.*; Yang, G. F.* Synthesis and biological evaluation of new MET inhibitors with 1,6-naphthyridinone scaffold. Eur. J. Med. Chem. 2020, 185, 111803. Chen, T.;# Zhuo, L. S.;# Liu, P. F.; Fang, W. R.; Li, Y. M.;* Huang, W.* Discovery of 1,6-Naphthyridinone-Based MET Kinase Inhibitor Bearing Quinoline Moiety as Promising Antitumor Drug Candidate. Eur. J. Med. Chem. 2020, 192, 112174. Zhuo, L. S.;# Xu, H. C.;# Wang, M. S.;# Zhao, X. E.; Ming, Z. H.; Zhu, X. L.; Huang, W.*; Yang, G. F.* 2,7-Naphthyridinone-Based MET Kinase Inhibitors: A Promising Novel Scaffold for Antitumor Drug Development. Eur. J. Med. Chem. 2019, 178, 705-714. Wang, Y. Z.;* Huang, W.;* Xin, M. H.; Chen, P.; Gui, L.; Zhao, X. X.; Zhu, X. R.; Tang, F.; Luo, H. P.; Cong, X.; Wang, J.; Liu, F.;* Discovery of potent anti-inflammatory4-(4,5,6,7-tetrahydrofuro[3,2-c]pyridin-2-yl)pyrimidin-2-amine for use as Janus kinase inhibitors. Bioorg. Med. Chem. 2019, 27, 2592-2597. She, N. F.; Zhuo, L. S.; Jiang, W.; Zhu, X. L.; Wang, J.; Ming, Z. H.; Zhao, X. E.; Cong, X.; Huang, W.* Design, Synthesis and Evaluation of Highly Selective Pyridone-based Class II MET Inhibitors. Bioorg. Med. Chem. Lett. 2014, 24, 3351-3355.